A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Four market realities new pharmaceutical commercial models should consider addressing

by Jeff Ford, Principal, Deloitte Consulting LLP, Principal, Deloitte Consulting LLP

The US pharmaceutical industry’s commercial market has historically been the Wild West. Under a fee-for-service environment, physicians and their patients made many of the care decisions with few restrictions. However, the changing health care landscape, including the move to a value-based health care system, has changed the ability of manufacturers to drive growth through the lever of price.   

Read more

Digital supply networks: A new imperative for life sciences

by Stephen Laaper, Principal, and John Allen, Senior Manager, Deloitte Consulting LLP

Life sciences companies are usually not considered market leaders in the race to embrace new technology and digital transformation. Whether deserved or not, this reputation—and the reality—should change. Without the advantages of digital, leaders in life sciences could lose competitive ground that can’t easily be regained.

It’s an urgent call to action, but also a huge opportunity.

Read more

Automation in clinical trials? It’s time to take the first step.

by Peter Russell, Principal, Deloitte Consulting LLP and Dawn Anderson, Managing Director, Deloitte Consulting LLP

Life sciences industry, it is time to start talking about robotics and cognitive analytics.

Actually, it’s time to start doing something about it. Many other industries are already there. Publishing, for example, or the automotive industry. Or financial services.

I hear you: “But we’re different. This is R&D in life sciences after all – not publishing.” It’s true – life sciences obviously operates within a web of regulatory oversight and complex science that makes for some unique challenges.

Read more

2018 outlook: Life sciences firms could see some legislative headwinds, regulatory momentum

by Greg Reh, Vice Chairman, US and Global Life Sciences Leader, Deloitte LLP

For many US life sciences and health care companies, 2017 was a year of market and legislative uncertainty. Much of the year was dominated by on-again-off-again efforts to repeal and replace the Affordable Care Act (ACA), which has now turned to discussions about reforming the tax code. For some life sciences companies, this uncertainty created a wait-and-see approach to investments – particularly mergers and acquisitions (M&A).

Read more

In an era of exponentials, health care is on the cusp of a potential major transformation

by Sarah Thomas, Managing Director, Deloitte Center for Health Solutions, Deloitte Services LP

As we look to move the ball forward with health IT, we’re closely watching exponential technologies and their potential power to transform the industry. Exponential technologies have the potential to render the health care sector unrecognizable in a relatively short amount of time. Artificial intelligence (AI), robotics, 3D printing, and synthetic biology all have the ability to potentially dramatically disrupt the systems and processes that have historically defined the health care industry.

Read more